- Home
- WLII vs IMUX Comparison
WLII vs IMUX Comparison
Compare WLII & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WLII | IMUX |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.1M | 209.2M |
| IPO Year | 2026 | 2013 |
Fundamental Metrics
Financial Performance| Metric | WLII | IMUX |
|---|---|---|
| Price | $10.26 | $14.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $36.00 |
| AVG Volume (30 Days) | 55.9K | ★ 182.6K |
| Earning Date | N/A | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.16 | $0.51 |
| 52 Week High | $10.29 | $15.84 |
Technical Indicators
Market Signals| Indicator | WLII | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 78.57 | 58.08 |
| Support Level | $10.16 | $0.74 |
| Resistance Level | $10.29 | $15.81 |
| Average True Range (ATR) | 0.03 | 0.90 |
| MACD | 0.01 | -0.17 |
| Stochastic Oscillator | 76.92 | 40.69 |
Price Performance
Historical ComparisonAbout WLII Willow Lane Acquisition Corp. II Class A Ordinary Shares
Willow Lane Acquisition Corp II is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.